Insurers pay more for multiple sclerosis drug because rebates don’t help, report says

(By Ed Silverman for STAT)

Drug makers may offer rebates to payers, but health plans continue to see notable increases in costs for prescription medicines, according to a report¹ by the office of Massachusetts Attorney General Maura Healey. And this has been especially true for one particularly costly group of medicines used to treat multiple sclerosis². Continue reading article here…..

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.